pib

PiB (Pittsburgh Compound-B) is a standard for analysis of 11C-PiB. 11C-PiB is a β-amyloid PET imaging tracer for Alzheimer's disease diagnosis.

Obicetrapib (AMG-899) is an inhibitor of cholesteryl ester transfer protein.

Luminespib (VER-52296) is an HSP90 inhibitor that inhibits HSP90α and HSP90β (IC50=7.8 21 nM). Luminespib has antitumor activity and is used in studies of head and neck tumors, among others.

Ganetespib (STA-9090) is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90), exhibiting potential antineoplastic activity.

Epibrassinolide (BP55) (EBR) is a biologically active compound of the brassinosteroids, is a natural brassinosteroid (BR) derivative, is a plant regulator with a similar structure to mammalian steroids.

Onalespib (AT13387) is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.

Anacetrapib (MK-0859) (MK0859) is an effective, specific, reversible rhCETP and mutant CETP(C13S) inhibitor (IC50: 7.9 nM and 11.8 nM). Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

Epiblastin A is an inhibitor of Casein Kinase 1 (CK1). Epiblastin A engages CK1 isoenzymes in cell lysate and induces efficient conversion of epiblast stem cells (EpiSCs) into embryonic stem cells (cESCs).

DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC),DCPIB displayed superior selectivity toward TRESK with an IC50 of 0.14 μM, demonstrating at least 100-fold higher affinity over TREK1 TRAAK channels.

Pimitespib (TAS-116) is an ATP-competitive and highly specific HSP90α HSP90β inhibitor with inhibition constants (Kis) of 34.7 nM and 21.3 nM, respectively.

Trepibutone is an acidic drug with pH-independent release.

PU-H71 is an experimental inhibitor of Hsp90.

Epibatidine is an agonist of α7nACh with a Kd value of 100 nM. It is utilized in research related to Alzheimer's disease, Parkinson's disease, and schizophrenia.

Piboserod (SB-207266) (SB 207266) is a selective 5-HT(4) receptor antagonist.

Piboserod HCl is a selective antagonist of 5-HT4 and muscarinic receptor.

Torcetrapib (CP-529414) is a cholesteryl ester transfer protein (CETP) inhibitor designed to reduce the heterotypic transfer of cholesteryl ester from HDL to LDL and or VLDL. It failed in phase III trials due to an excess of deaths.

Epibatidine 2HCl is a potent nicotinic agonist.

Onalespib lactate is a second-generation, potent and selective HSP90 Inhibitor with antitumor activity.

Epibetulinic acid has anti-inflammatory activity, it exhibits potent inhibitory effects on NO and prostaglandin E(2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin.

Icapamespib (PU-HZ151), a potent HSP90 inhibitor, exhibits an EC50 of 5 nM and possesses the capability to cross the blood-brain barrier.

1. Epiberberine may be caused drug interactions based on CYP2D6 enzyme. 2. Epiberberine has anti-adipogenic effect is mediated by downregulation of the Raf MEK1 ERK1 2 and AMPKα Akt pathways during 3T3-L1 adipocyte differentiation. 3. Epiberberine, as the brightest FSA emitter among the alkaloids, can also serve as an efficient conformation probe for HTG DNA and discriminate the DNA G-quadruplex from the RNA counterpart.

Dalcetrapib (RO4607381), a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.

Alpibectir has antibacterial activity [1].

Evacetrapib (LY2484595) (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.